Eun Kyung Cho

University of Udine — Italy

Medicine · Health Sciences

36h-index13.5kcitations211works17.92yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(94), Lung Cancer Research Studies(40), Lung Cancer Diagnosis and Treatment(38), Gastric Cancer Management and Outcomes(34), Colorectal Cancer Treatments and Studies(34)

Publications206 total

Vitamins and minerals and their role in cancer: a comprehensive review
Frontiers in Nutrition·2026Open Access
Phase IB and II study of ribociclib with trastuzumab plus endocrine therapy in HR+/HER2+ advanced breast cancer patients: Korean Cancer Study Group BR 18-2 MINI trial.
Journal of Clinical Oncology·2025· 2 cited
Updated overall survival and ctDNA analysis in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib in the phase 1/2 LASER201 study
BMC Medicine·2024· 7 citedOpen Access
Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer
Cancer Immunology Immunotherapy·2024· 3 citedOpen Access
PPD01.06 Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non–Small Cell Lung Cancer: Preliminary Results of the EVOKE-2 Study
Journal of Thoracic Oncology·2024Open Access
Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201
Lung Cancer·2024· 8 citedOpen Access
Evaluation of the efficacy and safety of a 3-weekly TS-1 regimen as adjuvant therapy for stage II and III advanced gastric cancer: A pilot study.
Journal of Clinical Oncology·2024
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY
Breast Cancer Research and Treatment·2023· 16 citedOpen Access
797 Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2 negative metastatic breast cancer
Regular and Young Investigator Award Abstracts·2023Open Access
Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16)
European Journal of Cancer·2023· 12 citedOpen Access
Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial
Nature Medicine·2023· 97 citedOpen Access
Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset
Cancer Research and Treatment·2023· 5 citedOpen Access
Amivantamab and lazertinib in treatment-naïve <i>EGFR-</i>mutated advanced non–small-cell lung cancer (NSCLC): Long-term follow-up and ctDNA results from CHRYSALIS.
Journal of Clinical Oncology·2023· 7 cited
Data from Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer
2023Open Access
Supplementary Data from Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer
2023Open Access
Table S4 from Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer
2023Open Access
Table S4 from Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer
2023Open Access
Table S1 from Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer
2023Open Access
Table S1 from Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer
2023Open Access
Supplementary Data from Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer
2023Open Access
page 1 of 11Next →

Frequent Co-authors

Dong Bok Shin(21), Se Hoon Park(14), Byoung Chul Cho(13), Jae Hoon Lee(12), Junshik Hong(12), Ki Hyeong Lee(11), Keunchil Park(11), Jinny Park(11), Young Saing Kim(10), Joo-Hang Kim(9), Hee Kyung Ahn(9), Sun Jin Sym(9), Soo‐Mee Bang(9), Myung‐Ju Ahn(8), Young Joo Min(7), Sang‐We Kim(6), Hye Ryun Kim(5), Jong‐Mu Sun(5), Inkeun Park(5), Ji‐Youn Han(5)